EBOLA:FAVIPIRAVIR.

Favipiravir also known as T-705 is an experimental anti-viral drug with activity against many RNA VIRUSES. It, like some other experimental antiviraldrugs (T-1105 and T-1106), is a pyrazinecarboxamide  derivative. Favipiravir is active against influenza viruses,West Nile virus,yellow fever virus,foot and mouth disease virus as well as other flaviviruses,arenaviruses,bunyaviruses and alphaviruses.
The mechanism of its actions is thought to be related to the selective inhibition of viral RNa-dependent RNA polymerase. Favipiravir does not inhibit RNA of DNA synthesis in mammalian cells and is not toxic to them.
The advantage of using favipiravir in an Ebola outbreak is that it has already been extensively tested for use as an anti-viral in human trials for influenza. The drug is now in a U.S. final-stage trial for treating influenza.
In addition, the drug is a pill, unlike the cocktail of injected antibodies administered to two Americans who got Ebola. This means it may be easier to use in rural locations with limited medical infrastructure.

Photographer:EPA
Liberian nurses carry an Ebola victim from a house for burial in the Banjor Community.
On August 5, a spokeswoman for MediVector declined to comment on the possibility of human use of the drug in Ebola, and deferred questions on subject to the Department of Defense.

Popular posts from this blog

UK GENERAL ELECTIONS:Inquiry announced into memo alleging Sturgeon wants Tory election victory.

Ebola Outbreak: Guinea Declares Emergency As Overall Deaths From Ebola Rise To 1,069